The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Total Neoadjuvant Therapy vs Standard Therapy in Locally Advanced Rectal Cancer: A Systematic Review and Meta-analysis
Open accessAbstract
Importance: Standard therapy for locally advanced rectal cancer includes concurrent chemoradiotherapy followed by surgery and adjuvant chemotherapy (CRT plus A). An alternative strategy known as total neoadjuvant therapy (TNT) involves administration of CRT plus neoadjuvant chemotherapy before surgery with the goal of delivering uninterrupted systemic therapy to eradicate micrometastases. A comparison of these 2 approaches has not been systematically reviewed previously. Objective: To determine the differences in rates of pathologic complete response (PCR), disease-free and overall survival, sphincter-preserving surgery, and ileostomy between patients receiving TNT vs standard CRT plus A. Data Sources: MEDLINE (via PubMed) and Embase (via OVID) were searched from inception through July 1, 2020, for the following terms: anal/anorectal neoplasms OR anal/anorectal cancer AND total neoadjuvant treatment OR total neoadjuvant therapy. Only studies in English were included. Study Selection: Randomized clinical trials or prospective/retrospective cohort studies comparing outcomes in patients with locally advanced rectal cancer who received TNT vs CRT plus A. Data Extraction and Synthesis: Data regarding the first author, publication year, location, sample size, and rates of PCR, sphincter-preserving surgery, ileostomy, and disease-free and overall survival were extracted using Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines and pooled using a random-effects model. Main Outcomes and Measures: Rates of PCR, sphincter-preserving surgery, ileostomy, and disease-free and overall survival. Results: After reviewing 2165 reports, 7 unique studies including a total of 2416 unique patients, of whom 1206 received TNT, were selected. The median age for the patients receiving TNT ranged from 57 to 69 years, with 58% to 73% being male. The pooled prevalence of PCR was 29.9% (range, 17.2%-38.5%) in the TNT group and 14.9% (range, 4.2%-21.3%) in the CRT plus A group. Total neoadjuvant therapy was associated with a higher chance of achieving a PCR (odds ratio [OR], 2.44; 95% CI, 1.99-2.98). No statistically significant difference in the proportion of sphincter-preserving surgery (OR, 1.06; 95% CI, 0.73-1.54) or ileostomy (OR, 1.05; 95% CI, 0.76-1.46) between recipients of TNT and CRT plus A was observed. Only 3 studies presented data on disease-free survival, and pooled analysis showed significantly higher odds of improved disease-free survival in patients who received TNT (OR, 2.07; 95% CI, 1.20-3.56; I2 = 49%). Data on overall survival were not consistently reported. Conclusions and Relevance: The findings of this systematic review and meta-analysis suggest that TNT is a promising strategy in locally advanced rectal cancer, with superior rates of PCR compared with standard therapy. However, the long-term effect on disease recurrence and overall survival needs to be explored in future studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Siegel, R. L., Miller, K. D., & Jemal, A. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21590 · Cited by 20,444
Maas, M., Nelemans, P. J., Valentini, V., Das, P., Rödel, C., Kuo, L.-J., Calvo, F. A., García-Aguilar, J., Glynne-Jones, R., Haustermans, K., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70172-8 · Cited by 1,945
Habr-Gama, A., Perez, R. O., Nadalin, W., Sabbaga, J., Ribeiro, U., Silva e Sousa, A. H., Campos, F. G., Kiss, D. R., & Gama-Rodrigues, J. (2004) · Annals of Surgery · doi:10.1097/01.sla.0000141194.27992.32 · Cited by 1,893
Bujko, K., Nowacki, M. P., Nasierowska-Guttmejer, A., Michalski, W., Bebenek, M., & Kryj, M. (2006) · British Journal of Surgery · doi:10.1002/bjs.5506 · Cited by 1,244
Prognostic Significance of Tumor Regression After Preoperative Chemoradiotherapy for Rectal Cancer
Rödel, C., Martus, P., Papadoupolos, T., Füzesi, L., Klimpfinger, M., Fietkau, R., Liersch, T., Hohenberger, W., Raab, R., Sauer, R., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.1329 · Cited by 1,215
van der Valk, M. J. M., Hilling, D. E., Bastiaannet, E., Meershoek-Klein Kranenbarg, E., Beets, G. L., Figueiredo, N. L., Habr-Gama, A., Perez, R. O., Renehan, A. G., van de Velde, C. J. H., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31078-x · Cited by 1,113
Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Al-Hawary, M. M., Cederquist, L., Chen, Y.-J., Ciombor, K. K., Cohen, S., Cooper, H. S., Deming, D., Engstrom, P. F., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0061 · Cited by 944
Bosset, J.-F., Calais, G., Mineur, L., Maingon, P., Stojanovic-Rundic, S., Bensadoun, R.-J., Bardet, E., Beny, A., Ollier, J.-C., Bolla, M., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70599-0 · Cited by 730
Garcia-Aguilar, J., Chow, O. S., Smith, D. D., Marcet, J. E., Cataldo, P. A., Varma, M. G., Kumar, A. S., Oommen, S., Coutsoftides, T., Hunt, S. R., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00004-2 · Cited by 697
Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer
Cercek, A., Roxburgh, C. S. D., Strombom, P., Smith, J. J., Temple, L. K. F., Nash, G. M., Guillem, J. G., Paty, P. B., Yaeger, R., Stadler, Z. K., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.0071 · Cited by 650
Dossa, F., Chesney, T. R., Acuna, S. A., & Baxter, N. N. (2017) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(17)30074-2 · Cited by 621
Fokas, E., Allgäuer, M., Polat, B., Klautke, G., Grabenbauer, G. G., Fietkau, R., Kuhnt, T., Staib, L., Brunner, T., Grosu, A.-L., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00308 · Cited by 549
Chau, I., Brown, G., Cunningham, D., Tait, D., Wotherspoon, A., Norman, A. R., Tebbutt, N., Hill, M., Ross, P. J., Massey, A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.4875 · Cited by 474
Kalady, M. F., de Campos-Lobato, L. F., Stocchi, L., Geisler, D. P., Dietz, D., Lavery, I. C., & Fazio, V. W. (2009) · Annals of Surgery · doi:10.1097/sla.0b013e3181b91e63 · Cited by 386
Sainato, A., Cernusco Luna Nunzia, V., Valentini, V., De Paoli, A., Maurizi, E. R., Lupattelli, M., Aristei, C., Vidali, C., Conti, M., Galardi, A., et al. (2014) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2014.10.006 · Cited by 288
Hupkens, B. J. P., Martens, M. H., Stoot, J. H., Berbee, M., Melenhorst, J., Beets-Tan, R. G., Beets, G. L., & Breukink, S. O. (2017) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000000862 · Cited by 272
The quality of life after rectal excision for low rectal cancer
Williams, N. S., & Johnston, D. (1983) · Journal of British Surgery · doi:10.1002/bjs.1800700805 · Cited by 259
(2006) · doi:10.1002/(issn)1365-2168 · Cited by 246
van der Valk, M. J. M., Marijnen, C. A. M., van Etten, B., Dijkstra, E. A., Hilling, D. E., Kranenbarg, E. M.-K., Putter, H., Roodvoets, A. G. H., Bahadoer, R. R., Fokstuen, T., et al. (2020) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2020.03.011 · Cited by 213
Habr-Gama, A., Perez, R. O., Proscurshim, I., Nunes dos Santos, R. M., Kiss, D., Gama-Rodrigues, J., & Cecconello, I. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.11.035 · Cited by 211
Hasan, S., Renz, P. B., Wegner, R. E., Finley, G. G., Raj, M. S., Monga, D. K., McCormick, J., & Kirichenko, A. V. (2018) · Annals of Surgery · doi:10.1097/sla.0000000000003051 · Cited by 157
Erlandsson, J., Lörinc, E., Ahlberg, M., Pettersson, D. R., Holm, T., Glimelius, B. L. G., & Martling, A. (2019) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2019.03.016 · Cited by 142
Polanco, P. M., Mokdad, A. A., Zhu, H., Choti, M. A., & Huerta, S. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.0231 · Cited by 105
Fokas, E., Fietkau, R., Hartmann, A., Hohenberger, W., Grützmann, R., Ghadimi, M. B., Liersch, T., Ströbel, P., Grabenbauer, G. G., Graeven, U., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy143 · Cited by 101
Markovina, S. T., Youssef, F. F., Roy, A., Aggarwal, S., Khwaja, S. S., DeWees, T. A., Tan, B. R., Hunt, S. R., Myerson, R. J., Chang, D. T., et al. (2017) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2017.05.048 · Cited by 99
Calvo, F. Á., Serrano, J., Díaz-González, J. A., Gómez-Espí, M., Lozano, E. B., García, R. P., de la Mata, D., Arranz, J. Á., Alfonso, P. G., Pérez-Manga, G., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl085 · Cited by 92
Yuki, S., Bando, H., Tsukada, Y., Inamori, K., Komatsu, Y., Homma, S., Uemura, M., Kato, T., Kotani, D., Fukuoka, S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.4100 · Cited by 73
O’Connell, E., Reynolds, I. S., McNamara, D. A., Prehn, J. H. M., & Burke, J. P. (2020) · Surgical Oncology · doi:10.1016/j.suronc.2020.03.009 · Cited by 41
George, T. J., Yothers, G., Hong, T. S., Russell, M. M., You, Y. N., Parker, W., Jacobs, S. A., Lucas, P. C., Gollub, M. J., Hall, W. A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.3505 · Cited by 33
Lim, Y. J., Kim, Y., & Kong, M. (2019) · Scientific Reports · doi:10.1038/s41598-019-46457-5 · Cited by 21
Shamseddine, A. I., Zeidan, Y. H., Kreidieh, M., Khalifeh, I. M., Turfa, R., Kattan, J. G., Mukherji, D., Temraz, S. N., Alqasem, K. S., Amarin, R., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-07333-y · Cited by 20
Cited by
Fokas, E., Schlenska-Lange, A., Polat, B., Klautke, G., Grabenbauer, G. G., Fietkau, R., Kuhnt, T., Staib, L., Brunner, T., Grosu, A.-L., et al. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2021.5445 · Cited by 360
Neoadjuvant relatlimab and nivolumab in resectable melanoma
Amaria, R. N., Postow, M., Burton, E. M., Tetzlaff, M. T., Ross, M. I., Torres-Cabala, C., Glitza, I. C., Duan, F., Milton, D. R., Busam, K., et al. (2022) · Nature · doi:10.1038/s41586-022-05368-8 · Cited by 345
Colon and rectal cancer: An emergent public health problem
Pinheiro, M., Moreira, D. N., & Ghidini, M. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i7.644 · Cited by 80
Raichurkar, P., Denehy, L., Solomon, M., Koh, C., Pillinger, N., Hogan, S., McBride, K., Carey, S., Bartyn, J., Hirst, N., et al. (2023) · Annals of Surgical Oncology · doi:10.1245/s10434-023-14192-x · Cited by 53
Metadata
- Authors
- Kasi, A., Abbasi, S., Handa, S., Al-Rajabi, R., Saeed, A., Baranda, J., & Sun, W.
- Venue
- JAMA Network Open
- Publisher
- American Medical Association (AMA)
- Published
- 2020-12-16
- Volume
- 3
- Issue
- 12
- Pages
- e2030097
- ISSN
- 2574-3805 (ISSN-L)
- OpenAlex
- W3111631690
- Cited by
- 388
- References
- 32
- FWCI
- 14.44
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.